Quoin Pharmaceuticals, Ltd. QNRX
At closeNov 3, 2026, 4:00 PM EST
After hours · Nov 3, 4:00 PM ET
- YTD
- -72.77%
- 1 year
- -61.96%
- Market cap
- 18.88M
- EPS (ttm)
- -5.47
- Shares out
- 5.05M
- Forward P/E
- -0.43
- YTD return
- -72.77%
- 1-year return
- -61.96%
- Volume
- 20.76K
- Avg volume
- 544.47K
- Open
- 4.11
- Previous close
- 4.02
- Day's range
- 3.90 – 4.34
- 52-week range
- 3.25 – 23.50
- Beta
- 1.89
- Analysts
- Strong Buy
- Price target
- 4.50 (+14.5%)
6M -2.43 (-38.21%)
Key statistics
- Enterprise value
- -6.59M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.05M
- Total cash
- 12.57M
- Total debt
- 3.22M
- Return on equity
- -100.03%
- Short % of float
- 0.48%
- 50-day average
- 0.69104
- 200-day average
- 0.6863
Analyst view
Consensus: strong buy
- Target (low)
- 1.50
- Target (mean)
- 4.50
- Target (high)
- 10.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.43.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.44 | -0.47 | -0.03 | -6.82% |
| Aug 8, 2024 | Jun 1, 2024 | -0.75 | -0.39 | +0.36 | +48.00% |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -1.11 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | -2.37 | -2.08 | +0.29 | +12.24% |
| Nov 8, 2023 | Sep 1, 2023 | -2.40 | -1.95 | +0.45 | +18.75% |
| Aug 2, 2023 | Jun 1, 2023 | 0.00 | -2.13 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 15, 2024 | Maxim Group | main | Buy | Buy |
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- quoinpharma.com
News
12 Health Care Stocks Moving In Monday's After-Market Session 
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 
Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome 
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy 
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18 
Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome 
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome 
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14 
12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on QNRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER DENISE P | Chief Operating Officer | Purchase | Sep 3, 2024 | 47,092 |
| DUNN GORDON | Chief Financial Officer | Purchase | Sep 9, 2024 | 28,856 |
| MYERS MICHAEL | Chief Executive Officer | Purchase | Sep 3, 2024 | 47,252 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 0.77% | 38,691 | 20.20K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.63% | 31,854 | 16.63K | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 0.50% | 25,119 | 13.11K | Sep 29, 2024 |
| Virtu Financial LLC | 0.50% | 25,165 | 13.14K | Sep 29, 2024 |
| UBS Group AG | 0.45% | 22,821 | 11.91K | Sep 29, 2024 |
| Rhumbline Advisers | 0.41% | 20,786 | 10.85K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 95 | 49 | Apr 29, 2024 |